Ensysce Competitors
| ENSC Stock | USD 0.61 0.15 32.61% |
Ensysce Biosciences vs Can Fite Correlation
Almost no diversification
The correlation between Ensysce Biosciences and CANF is 0.94 (i.e., Almost no diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Ensysce Biosciences and CANF in the same portfolio, assuming nothing else is changed.
Moving together with Ensysce Stock
Moving against Ensysce Stock
| 0.87 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.81 | DSGN | Design Therapeutics | PairCorr |
| 0.73 | ENGN | enGene Holdings Common | PairCorr |
| 0.58 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.53 | 63E | ONWARD MEDICAL BV | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ensysce Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Ensysce Biosciences Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Ensysce Biosciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Ensysce and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Ensysce Biosciences does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Ensysce Stock performing well and Ensysce Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ensysce Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SNGX | 3.64 | (0.32) | 0.00 | (0.08) | 0.00 | 8.16 | 30.10 | |||
| TTNP | 3.46 | 0.41 | 0.03 | (0.16) | 5.38 | 9.38 | 30.41 | |||
| OGEN | 3.46 | (0.68) | 0.00 | (12.29) | 0.00 | 7.32 | 24.70 | |||
| KALA | 6.10 | (0.61) | 0.00 | (0.33) | 0.00 | 12.28 | 59.48 | |||
| XBIO | 3.11 | (0.48) | 0.00 | (0.29) | 0.00 | 4.76 | 20.89 | |||
| AIM | 4.59 | (0.69) | 0.00 | (4.17) | 0.00 | 10.14 | 29.72 | |||
| VYNE | 3.10 | 0.88 | 0.21 | 8.43 | 2.34 | 5.71 | 55.08 | |||
| QLGN | 5.09 | (0.57) | 0.00 | 1.42 | 0.00 | 10.42 | 26.37 | |||
| KZIA | 8.07 | (0.18) | 0.01 | 0.05 | 10.39 | 14.69 | 78.79 | |||
| CANF | 5.00 | (0.60) | 0.00 | 0.45 | 0.00 | 10.40 | 38.42 |
Cross Equities Net Income Analysis
Compare Ensysce Biosciences and related stocks such as Soligenix, Titan Pharmaceuticals, and Oragenics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNGX | (1.2 M) | (2.4 M) | (4.2 M) | (10.1 M) | (6.7 M) | (7.8 M) | (3.2 M) | (7.1 M) | (8.9 M) | (9.4 M) | (17.7 M) | (12.6 M) | (13.8 M) | (6.1 M) | (8.3 M) | (7.4 M) | (7.8 M) |
| OGEN | (1.7 M) | (7.7 M) | (13.1 M) | (16.1 M) | (5.8 M) | (11.7 M) | (7 M) | (6.7 M) | (9.9 M) | (15.6 M) | (26.4 M) | (15.7 M) | (14.3 M) | (20.7 M) | (10.6 M) | (9.5 M) | (10 M) |
| KALA | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (19.4 M) | (16.7 M) | (33.2 M) | (42.2 M) | (66.7 M) | (94.3 M) | (104.3 M) | (142.6 M) | (44.8 M) | (42.2 M) | (38.5 M) | (34.7 M) | (36.4 M) |
| XBIO | (6.3 M) | (6.3 M) | (6.3 M) | (8.6 M) | (14.3 M) | (12.5 M) | (54.2 M) | (3.6 M) | (7.3 M) | (12.8 M) | (10.9 M) | (5.6 M) | (6.6 M) | (4.1 M) | (4 M) | (4.6 M) | (4.8 M) |
| AIM | (1.8 M) | (9 M) | (17.4 M) | (16.2 M) | (17.4 M) | (15.2 M) | (7.5 M) | (8.3 M) | (9.8 M) | (9.4 M) | (14.4 M) | (19.1 M) | (19.4 M) | (29 M) | (17.3 M) | (15.6 M) | (16.4 M) |
| VYNE | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (14.1 M) | (29.1 M) | (51.4 M) | (70.5 M) | (255.6 M) | (73.3 M) | (23.2 M) | (28.5 M) | (39.8 M) | (35.9 M) | (37.6 M) |
| KZIA | (17.1 M) | 1.3 M | (1 M) | (7.5 M) | (7.1 M) | (12.1 M) | (10.7 M) | (6 M) | (10.3 M) | (12.5 M) | (8.4 M) | (25 M) | (20.5 M) | (26.8 M) | (20.7 M) | (23.8 M) | (25 M) |
| CANF | (3.7 M) | (6.7 M) | (5.6 M) | (8.3 M) | (6.1 M) | (4.8 M) | (6.9 M) | (5 M) | (6.6 M) | (12.6 M) | (14.4 M) | (12.6 M) | (10.2 M) | (7.6 M) | (7.9 M) | (7.1 M) | (7.4 M) |
Ensysce Biosciences and related stocks such as Soligenix, Titan Pharmaceuticals, and Oragenics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Ensysce Biosciences financial statement analysis. It represents the amount of money remaining after all of Ensysce Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Ensysce Biosciences Competitive Analysis
The better you understand Ensysce Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Ensysce Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Ensysce Biosciences' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Ensysce Biosciences Competition Performance Charts
Five steps to successful analysis of Ensysce Biosciences Competition
Ensysce Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Ensysce Biosciences in relation to its competition. Ensysce Biosciences' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Ensysce Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Ensysce Biosciences' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Ensysce Biosciences, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Ensysce Biosciences position
In addition to having Ensysce Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Market Neutral Funds Thematic Idea Now
Market Neutral Funds
Funds or Etfs that invest in both long and short positions of different entities to enhance returns from broad market movements over time. The Market Neutral Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Market Neutral Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Ensysce Biosciences Correlation with its peers. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Will Biotechnology sector continue expanding? Could Ensysce diversify its offerings? Factors like these will boost the valuation of Ensysce Biosciences. Projected growth potential of Ensysce fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ensysce Biosciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.35) | Revenue Per Share | Quarterly Revenue Growth (0.86) | Return On Assets | Return On Equity |
Investors evaluate Ensysce Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ensysce Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ensysce Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Ensysce Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ensysce Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Ensysce Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.